1,109
Views
11
CrossRef citations to date
0
Altmetric
Editorials

Toll like receptors: a new hope on the horizon to treat multiple sclerosis

, , &
Pages 1277-1279 | Published online: 27 Aug 2014
 

Abstract

Evolving data have shown that the toll like receptors (TLRs) family of innate immune receptors has an important role in driving the activation and inhibition of pathogenic pathways involved in multiple sclerosis (MS). While developing clinical trials targeting MS by TLRs modulators are of considerable interest, several of them have failed. Herein, the various consequences of TLRs pathways activation and the potential of targeting these receptors for therapeutic purposes are described. In particular, different aspects of TLR based therapies are discussed, in order to develop more efficacious and safe therapies targeting inflammatory and autoimmune diseases, especially MS.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Notes

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.